Go back Corporate News

DEPLOY AMENDS TERMS OF OFFERING IN CONNECTION WITH PROPOSED REVERSE TAKEOVER

Body and Mind
Body and Mind May 25, 2017

VANCOUVER, BC, May 25, 2017 – Deploy Technologies Inc. (CSE: DEP, OTC: DPLY) (“Deploy” or the “Company”) announces that it has amended the terms of its private placement pursuant to its news release dated May 17, 2017, in connection with its proposed reverse takeover transaction with Nevada Medical Group LLC (the “RTO”).

The private placement (the “Concurrent Financing”) will consist of subscription receipts of Deploy (the “Subscription Receipts”), at an issue price of $0.22 per Subscription Receipt, with each Subscription Receipt being automatically converted, at no additional cost to the subscriber, upon the completion of the RTO for one Deploy Share and one Deploy Share purchase warrant (the “Warrant”) exercisable at a price of $0.30 for a period of 24 months from the date of issuance. Each Warrant is subject to acceleration provisions following the six-month anniversary of the date of Closing, if the closing trading price of the Deploy Shares on the Exchange is equal to or greater than $0.40 for seven consecutive trading days, at which time the Company may accelerate the expiry date of the Warrants by issuing a press release announcing the reduced warrant term whereupon the Warrants will expire 21 calendar days after the date of such press release.

The Concurrent Financing must raise a minimum of US$4,000,000. The Company intends to issue up to 45,454,545 Units for maximum gross proceeds of $10,000,000 in connection with the Concurrent Financing. The proceeds will be used to fund the RTO and to fund the operations of the resulting issuer on completion of the RTO.

The Concurrent Financing will be completed on a non-brokered basis, and the Company may pay finder’s fees in accordance with applicable securities laws and Exchange policies to eligible finders. Completion of the Concurrent Financing is subject to receipt of Exchange approval and other requisite approvals. All securities issued in connection with the Concurrent Financing will be subject to hold periods under applicable Canadian and United States securities laws for a minimum of four months and a day.

The securities referenced herein have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registrations or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

For further information please contact:
Murray Simser,

CEO Deploy Technologies Inc.

Email: justin@altuscapital.ca

Completion of the proposed transaction is subject to a number of conditions, including receipt of appropriate regulatory approvals. The transaction cannot close until all such conditions are satisfied. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the disclosure document to be prepared in connection with the transaction, any information released or received with respect to the Acquisition may not be accurate or complete
and should not be relied upon. Trading in securities of Deploy Technologies Inc. should be considered highly speculative.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, the results of financing efforts and the parties’ due diligence reviews, and general market conditions – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

We seek safe harbour.

Body and Mind
Body and Mind May 25, 2017

Related Articles

  • Corporate News

    Body and Mind Announces Q2 2024 Financial Results

    Las Vegas, NV and Vancouver, B.C., Canada (March 26, 2024) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state operations-focused cannabis company, is pleased to announce its financial results for the second quarter of fiscal year 2024 ended January 31, 2024 and to provide shareholders with an operational update.…

    Body and Mind · March 26, 2024
  • Corporate News

    Body and Mind Provides Update on Optimization Initiatives

    Las Vegas, NV and Vancouver, B.C., Canada (February 1, 2024) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state operations-focused cannabis company, is pleased to announce updates on its dispensary development schedules and the divestment of the Company’s cultivation and processing operations in Nevada, which is owned through the…

    Body and Mind · February 1, 2024
  • Corporate News

    Body and Mind Awarded State Approval for New Jersey Dispensary

    Las Vegas, NV and Vancouver, B.C., Canada (January 23, 2024) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state operations-focused cannabis company, is pleased to announce the State of New Jersey Cannabis Regulatory Commission has approved the application for an Annual Class 5 Cannabis Retailer license to operate an…

    Body and Mind · January 23, 2024
image description